These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 27273040)

  • 1. Research topic: Managing compassionate therapy-the role of the virtual clinic.
    Ward M
    J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():44-5. PubMed ID: 27273040
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
    Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
    Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Biosimilars [Inflectra®] in the Management of Acute Severe Ulcerative Colitis.
    Harkin G; Keogh Á; Slattery E
    J Crohns Colitis; 2017 Oct; 11(11):1400-1401. PubMed ID: 28444254
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease.
    Tighe D; McNamara D
    World J Gastroenterol; 2017 Jan; 23(3):414-425. PubMed ID: 28210077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower Dose Infliximab for Ulcerative Colitis: How Low Can We Go and How Much Can be Saved?
    Christophi GP; Ciorba MA
    J Clin Gastroenterol; 2015 Aug; 49(7):539-40. PubMed ID: 26057322
    [No Abstract]   [Full Text] [Related]  

  • 6. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission.
    Amiot A; Hulin A; Belhassan M; Andre C; Gagniere C; Le Baleur Y; Farcet JP; Delchier JC; Hüe S
    Clin Res Hepatol Gastroenterol; 2016 Feb; 40(1):90-8. PubMed ID: 26138132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Value of Proactive Infliximab Drug Monitoring in Patients With Inflammatory Bowel Disease.
    Orfanoudaki E; Foteinogiannopoulou K; Theodoraki E; Koutroubakis IE
    Inflamm Bowel Dis; 2020 May; 26(6):e50. PubMed ID: 32206807
    [No Abstract]   [Full Text] [Related]  

  • 9. Selective Use of Combination Therapy in Patients With Infliximab-resistant Inflammatory Bowel Disease: Data From a Tertiary Referral Center.
    Orlando A; Renna S; Rizzuto G; Orlando E; Affronti M; Cottone M
    Clin Gastroenterol Hepatol; 2016 Jun; 14(6):914. PubMed ID: 26707682
    [No Abstract]   [Full Text] [Related]  

  • 10. Golimumab for moderately to severely active ulcerative colitis.
    Kedia S; Ahuja V; Makharia GK
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe Eosinophilic Gastroenteritis in a Crohn's Disease Patient Treated With Infliximab and Adalimumab.
    Muir A; Surrey L; Kriegermeier A; Shaikhkalil A; Piccoli DA
    Am J Gastroenterol; 2016 Mar; 111(3):437-8. PubMed ID: 27018120
    [No Abstract]   [Full Text] [Related]  

  • 12. Biologic Therapeutic Drug Monitoring in Australia.
    J Connor S
    J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():8-9. PubMed ID: 26990573
    [No Abstract]   [Full Text] [Related]  

  • 13. Safe and effective: anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis.
    Kiely CJ; Subramaniam K; Platten J; Pavli P
    Intern Med J; 2016 May; 46(5):616-9. PubMed ID: 27170239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
    Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications?
    Nuij V; Fuhler GM; Edel AJ; Ouwendijk RJ; Rijk MC; Beukers R; Quispel R; van Tilburg AJ; Tang TJ; Smalbraak H; Bruin KF; Lindenburg F; Peyrin-Biroulet L; van der Woude CJ;
    J Crohns Colitis; 2015 Nov; 9(11):997-1003. PubMed ID: 26223842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De-escalation of Infliximab Maintenance Therapy from 8- to 10-week Dosing Interval Based on Faecal Calprotectin in Patients with Crohn's Disease.
    Papamichael K; Karatzas P; Mantzaris GJ
    J Crohns Colitis; 2016 Mar; 10(3):371-2. PubMed ID: 26546496
    [No Abstract]   [Full Text] [Related]  

  • 17. Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice.
    Ampuero J; Rojas-Feria M; Castro-Fernández M; Millán-Lorenzo M; Guerrero-Jiménez P; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Jan; 31(1):112-8. PubMed ID: 26173493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease.
    Varma P; Paul E; Huang C; Headon B; Sparrow MP
    Intern Med J; 2016 Jul; 46(7):798-804. PubMed ID: 26865349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introduction.
    Gearry RB
    J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():23. PubMed ID: 27273032
    [No Abstract]   [Full Text] [Related]  

  • 20. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial.
    Louis E; Löfberg R; Reinisch W; Camez A; Yang M; Pollack PF; Chen N; Chao J; Mulani PM
    J Crohns Colitis; 2013 Feb; 7(1):34-43. PubMed ID: 22480772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.